- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/24 - Antidepressants
Patent holdings for IPC class A61P 25/24
Total number of patents in this class: 4293
10-year publication summary
|
115
|
164
|
244
|
297
|
310
|
371
|
410
|
427
|
364
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2945 |
74 |
| Janssen Pharmaceutica N.V. | 3625 |
72 |
| Antecip Bioventures II LLC | 315 |
65 |
| F. Hoffmann-La Roche AG | 7942 |
60 |
| Sage Therapeutics, Inc. | 349 |
54 |
| Taisho Pharmaceutical Co., Ltd. | 861 |
43 |
| AstraZeneca AB | 2961 |
40 |
| H. Lundbeck A/S | 1247 |
40 |
| Hoffmann-La Roche Inc. | 3252 |
37 |
| GH Research Ireland Limited | 39 |
29 |
| Sumitomo Dainippon Pharma Co., Ltd. | 220 |
27 |
| Intra-Cellular Therapies, Inc. | 393 |
25 |
| Boehringer Ingelheim International GmbH | 4762 |
23 |
| LTS Lohmann Therapie-Systeme AG | 704 |
23 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 803 |
23 |
| Sunshine Lake Pharma Co., Ltd. | 567 |
23 |
| The Regents of the University of California | 19479 |
22 |
| Les Laboratoires Servier | 596 |
22 |
| Glaxo Group Limited | 4286 |
21 |
| Janssen Pharmaceuticals, Inc. | 411 |
21 |
| Other owners | 3549 |